Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

15.7%

95 terminated/withdrawn out of 604 trials

Success Rate

76.9%

-9.6% vs industry average

Late-Stage Pipeline

1%

9 trials in Phase 3/4

Results Transparency

59%

186 of 316 completed trials have results

Key Signals

93 recruiting186 with results71 terminated24 withdrawn

Enrollment Performance

Analytics

Phase 2
189(35.4%)
Phase 1
173(32.4%)
N/A
135(25.3%)
Early Phase 1
28(5.2%)
Phase 3
6(1.1%)
Phase 4
3(0.6%)
534Total
Phase 2(189)
Phase 1(173)
N/A(135)
Early Phase 1(28)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (604)

Showing 20 of 604 trials
NCT06109467Phase 2Active Not Recruiting

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Role: lead

NCT05076760Phase 1Recruiting

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Role: collaborator

NCT07638150Not ApplicableNot Yet Recruiting

PRehabilitation Intervention to Modify Eating for Breast Cancer Patients (PRIME)

Role: lead

NCT04955730Phase 2Completed

NPWT in Patients Undergoing Surgical Procedures for Management of GI Malignancies

Role: lead

NCT05177211Phase 2Completed

Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL)

Role: lead

NCT06835387Phase 2Recruiting

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors

Role: collaborator

NCT02450708Not ApplicableActive Not Recruiting

Selection of Allogeneic Hematopoietic Cell Donors Based on KIR and HLA Genotypes

Role: collaborator

NCT05664178Phase 1Completed

Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology

Role: lead

NCT04975152Phase 1Recruiting

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Role: lead

NCT05687188Recruiting

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

Role: lead

NCT04588545Phase 1Active Not Recruiting

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

Role: lead

NCT06337552Not ApplicableActive Not Recruiting

High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial)

Role: lead

NCT06199726Active Not Recruiting

REFLECT: Reproductive Education and Fertility Links for Cancer Treatment

Role: lead

NCT07218848Not ApplicableActive Not Recruiting

ProSalud in Latinos Living in Rural/Agricultural Communities Within Moffitt's Catchment Area

Role: lead

NCT04879940Phase 2Active Not Recruiting

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization

Role: lead

NCT06855212Phase 2Active Not Recruiting

Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC

Role: lead

NCT04585269Not ApplicableCompleted

Bright IDEAS - Young Adults Problem-Solving Skills Training

Role: collaborator

NCT07101861Not ApplicableCompleted

Breast Cancer Survivors RESET (Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools): A Pilot, Feasibility Study

Role: lead

NCT07447635Not ApplicableRecruiting

Testing an MBI for Smoking Cessation and Alcohol Use Among Cancer Survivors

Role: lead

NCT07111039Not ApplicableWithdrawn

Compare Airway Pressure Release Ventilation (APRV) to Conventional Mechanical Ventila

Role: lead